Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Sham Mailankody, Michaela Liedtke, Surbhi Sidana, Jeffrey V. Matous, Saurabh Chhabra, Olalekan O. Oluwole, Shahbaz A. Malik, Shaji Kumar, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Sundar Jagannath, Myo Htut, Noopur S. Raje, David S. Siegel, Erin E. Karski, Wade Lovelace, Afrodite Lourbakos, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari
Institutions: Memorial Sloan Kettering Cancer Center, Stanford Medicine, Stanford University, Colorado Blood Cancer Institute, Medical College of Wisconsin, Vanderbilt University Medical Center, St David's Medical Center, Mayo Clinic, Banner MD Anderson Cancer Center, Cleveland Clinic, Mount Sinai Hospital, City Of Hope National Medical Center, Massachusetts General Hospital, Hackensack University Medical Center, Allogene Therapeutics (United States)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3211947906